A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 tre — Charles Bernick (ATHIRA PHA
Abstract Alzheimer’s disease (AD) is the largest unmet medical need in neurology. The patient population in the US and globally is reaching epidemic proportions due to aging societies, yet no effectiv
| Project title | A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 tre |
|---|---|
| Project number | 5R01AG068268-02 |
| PI name | Charles Bernick |
| Institution | ATHIRA PHARMA, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $4.49M |
| Fiscal year | 2021 |
| Project start | 2020-09-15T00:00:00 |
| Project end | 2023-05-31T00:00:00 |
| Abstract | Abstract Alzheimer’s disease (AD) is the largest unmet medical need in neurology. The patient population in the US and globally is reaching epidemic proportions due to aging societies, yet no effectiv |
| Key terms | <6-OHDA><6-hydroxydopamine><A β-42><A β42><A-beta 42><A-beta42><AD dementia><AD pathology><APP-PS1>< |
$799/mo
Try GrantRadar →